Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline

Main recommendations

1. ESGE recommends small-bowel video capsule endoscopy as the first-line investigation in patients with obscure gastrointestinal bleeding (strong recommendation, moderate quality evidence).

2. In patients with overt obscure gastrointestinal bleeding, ESGE recommends performing small-bowel capsule endoscopy as soon as possible after the bleeding episode, optimally within 14 days, in order to maximize the diagnostic yield (strong recommendation, moderate quality evidence).

3. ESGE does not recommend the routine performance of second-look endoscopy prior to small-bowel capsule endoscopy; however, whether to perform second-look endoscopy before capsule endoscopy in patients with obscure gastrointestinal bleeding or iron-deficiency anaemia should be decided on a case-by-case basis (strong recommendation, low quality evidence).

4. In patients with positive findings at small-bowel capsule endoscopy, ESGE recommends device-assisted enteroscopy to confirm and possibly treat lesions identified by capsule endoscopy (strong recommendation, high quality evidence).

5. ESGE recommends ileocolonoscopy as the first endoscopic examination for investigating patients with suspected Crohn’s disease (strong recommendation, high quality evidence).

6. In patients with established Crohn’s disease, based on ileocolonoscopy findings, ESGE recommends dedicated cross-sectional imaging for small-bowel evaluation since this has the potential to assess extent and location of any Crohn’s disease lesions, to identify strictures, and to assess for extraluminal disease (strong recommendation, low quality evidence).

7. ESGE strongly recommends against the use of small-bowel capsule endoscopy for suspected coeliac disease but suggests that capsule endoscopy could be used in patients unwilling or unable to undergo conventional endoscopy (strong recommendation, low quality evidence).

ESGE does not recommend routine small-bowel imaging or the use of the PillCam patency capsule prior to capsule endoscopy in these patients (strong recommendation, low quality evidence).

In the presence of obstructive symptoms or known stenosis, ESGE recommends that dedicated small bowel cross-sectional imaging modalities such as magnetic resonance enterography/enteroclysis or computed tomography enterography/enteroclysis should be used first (strong recommendation, low quality evidence).

In patients with unremarkable or nondiagnostic findings from such cross-sectional imaging of the small bowel, ESGE recommends small-bowel capsule endoscopy as a subsequent investigation, if deemed to influence patient management (strong recommendation, low quality evidence).

When capsule endoscopy is indicated, ESGE recommends use of the PillCam patency capsule to confirm functional patency of the small bowel (strong recommendation, low quality evidence).

In patients with unremarkable or nondiagnostic findings from such cross-sectional imaging of the small bowel, ESGE recommends small-bowel capsule endoscopy as a subsequent investigation, if deemed to influence patient management (strong recommendation, low quality evidence).

Endoscopy 2015; 47: 352–376

 DOI http://dx.doi.org/10.1055/s-0034-1391555

© Georg Thieme Verlag KG Stuttgart · New York

ISSN 0013-726X

This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Guideline was also reviewed and endorsed by the British Society of Gastroenterology (BSG). It addresses the roles of small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders.

Authors

Marco Pennazio1, Cristiano Spada2, Rami Elbakri3, Martin Keuchel4, Andrea May5, Chris J. Mulder6, Emanuele Rondinotti7, Samuel N. Adler8, Joerg Albert9, Peter Baltes10, Federico Barbaro11, Christophe Cellier12, Jean Pierre Charton13, Michel Delvaux14, Edward J. Despott15, Dirk Domagk16, Amir Klein17, Mark McAlindon18, Bruno Rosa19, Georgina Rowse20, David S. Sanders21, Jean Christophe Saurin22, Reena Sidhu23, Jean-Marc Dumonceau24, Cesare Hassan25, Ian M. Grahn26

Institutions

Institutions listed at end of article.

Bibliography

ESGE Clinical Guideline

–

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Abbreviations

- **BSG** British Society of Gastroenterology
- **CECDAI** Capsule Endoscopy Crohn’s Disease Activity Index
- **CECT** contrast-enhanced computed tomography
- **CI** confidence interval
- **CT** computed tomography
- **CTA** computed tomography-angiography
- **CTE** computed tomography-enterography/enteroclysis
- **DBE** double-balloon enteroscopy
- **EATL** enteropathy associated T-cell lymphoma
- **EMA** endomysial antibodies
- **FAP** familial adenomatous polyposis
- **FOTB** faecal occult blood test
- **GRADE** Grading of Recommendations Assessment, Development and Evaluation
- **GIST** gastrointestinal stromal tumour
- **HLA** human leukocyte antigen
- **IBD** inflammatory bowel disease
- **IBDU** inflammatory bowel disease-unclassified
- **ICCE** International Conference on Capsule Endoscopy
- **IDA** iron-deficiency anaemia
- **MRE** magnetic resonance enterography/enteroclysis
- **MRI** magnetic resonance imaging
- **NPV** negative predictive value
- **NSAIDs** nonsteroidal anti-inflammatory drugs
- **OGD** oesophagogastroduodenoscopy
- **OGIB** obscure gastrointestinal bleeding
- **OR** odds ratio
- **PJS** Peutz-Jeghers syndrome
- **PPV** positive predictive value
- **RCD** refractory coeliac disease
- **RCT** randomized controlled trial
- **SBE** single-balloon enteroscopy
- **SBFT** small-bowel follow-through
- **tTG** tissue transglutaminase
- **VCE** (small-bowel) video capsule endoscopy

Introduction

The field of gastrointestinal endoscopy has made great strides over the past several decades, and endoscopists have mastered the art of advancing flexible video endoscopes in the upper and lower parts of the gastrointestinal tract. Endoscopic evaluation of the small bowel (i.e., enteroscopy), on the other hand, poses a unique challenge that has plagued physicians for decades. With the development of newer enteroscopic modalities, a more thorough evaluation is now possible. These new techniques comprise small-bowel video capsule endoscopy (VCE) and device-assisted enteroscopy; the latter includes double-balloon enteroscopy (DBE), single-balloon enteroscopy (SBE), spiral enteroscopy, and balloon-guided enteroscopy (see Box 1).

VCE has revolutionized small-bowel imaging by providing a reliable and noninvasive method for complete visualization and assessment of the mucosal surface. Given the increased detection of small-bowel disease by VCE, innovations in device-assisted enteroscopy have been crucial for histopathological confirmation, enabling endoscopic therapy in selected cases and thus avoiding the need for surgery. With these recent technological advances, enteroscopy currently has a pivotal role in the evaluation of patients with suspected small-bowel diseases, including obscure gastrointestinal bleeding (OGIB), iron-deficiency anaemia, suspected and known Crohn’s disease, tumours, polyposis syndromes, and coeliac disease.

This Guideline, commissioned by the European Society of Gastrointestinal Endoscopy (ESGE) and endorsed by the British Society of Gastroenterology (BSG), in addition to updating previous ESGE guidelines [1, 2], analyzes in detail the performance of VCE and device-assisted enteroscopy compared with nonendoscopic methods for the investigation of the small bowel. The aim of this evidence-based and consensus-based Guideline, is to provide caregivers with a comprehensive guide for the clinical application of enteroscopy.

Methods

The ESGE commissioned this Guideline and appointed a guideline leader (M.P.) who invited the listed authors to participate in the project development. The key questions were prepared by the coordinating team (M.P. and C.S.) and then approved by the other members. The coordinating team formed task force subgroups, each with its own coordinator, and divided the key topics amongst these task forces (see Appendix e1, available online). Each task force performed a systematic literature search to prepare evidence-based and well-balanced statements on their assigned key questions. The coordinating team independently performed systematic literature searches with the assistance of a librarian. The Medline, EMBASE and Trip databases were searched including at minimum the following key words: video capsule endoscopy (VCE), double-balloon enteroscopy (DBE), single-balloon endoscopy (SBE), spiral enteroscopy, small-bowel, and enteroscopy. All articles on the use of VCE and device-assisted enteroscopy in patients with OGIB, iron-deficiency anaemia, Crohn’s disease, small-bowel tumours, polyposis syndromes, and coeliac disease were selected by title or abstract. All selected articles were graded by the level of evidence and strength of recommendation according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [3, 4]. Evidence tables and Recommendations for assessment of guideline implementation are provided in Appendices e2 and e3 (available online).

Each task force prepared statements on their assigned key questions which were discussed and voted on during the plenary meeting held in November 2013. The literature searches were updated through to November 2014. In November 2014, a draft prepared by the coordinating team was sent to all group members. After agreement on a final version, the manuscript was submitted to Endoscopy for publication. The journal subjected the manuscript to peer review and the manuscript was amended to take into account the reviewers’ comments. All authors agreed on the final revised manuscript. The final revised manuscript was then reviewed and approved by the BSG. This Guideline was issued in 2015 and will be considered for review and update in 2019 or sooner if new relevant evidence becomes available. Any updates to the Guideline in the interim will be noted on the ESGE website: http://www.esge.com/esge-guidelines.html.
**Box 1 Types of small-bowel endoscopy**

**Small-bowel video capsule endoscopy**
Small-bowel video capsule endoscopy (VCE) is a method of endoluminal examination of the small bowel using a wireless disposable capsule-shaped tool which is swallowed and then propelled by gut motility through the gastrointestinal tract. From there it transmits images wirelessly to a data recorder worn by the patient. The types of VCE on the market vary according to manufacturer. The VCE system (PillCam, Covidien plc, Dublin, Ireland; Endocapsule, Olympus Optical Co, Tokyo, Japan; MiroCam, IntroMedic, Seoul, Korea; OMOM capsule, Jinshan Science and Technology Group, Chongqing, China) consists of three main components: a capsule endoscope; a sensing system with a data recorder, and a personal computer workstation with proprietary software for image review and interpretation. All these systems allow real-time review of images during VCE examinations. The CapsoCam (CapsoVision, Cupertino, California, USA) stores all images on a microchip and is designed to offer a 360° panoramic view with wire-free technology. This capsule system has no data transmission so that patients have to collect the capsule after expulsion in the stool and then send it back to the gastroenterology unit.

**Push-enteroscopy**
Push-enteroscopy is a transoral endoluminal examination of the proximal jejunum using a long, flexible endoscope. It is most frequently performed with dedicated push-enteroscopes. Push-enteroscopy does not enable visualization of distal portions of the small intestine but permits tissue sampling and endoscopic treatments of the proximal jejunum. In recent years, device-assisted enteroscopy (DAE) has largely replaced push-enteroscopy, enabling diagnostic and therapeutic procedures throughout the entire length of the small bowel.

**Device-assisted enteroscopy**
Device-assisted enteroscopy (DAE) is a generic term for endoluminal examination of the small bowel by any endoscopic technique that includes assisted progression, i.e. with a balloon, overtube, or other stiffening device. DAE includes double-balloon enteroscopy (DBE), single-balloon enteroscopy (SBE), spiral enteroscopy, and balloon-guided endoscopy. In contrast to VCE, DAE is labour-intensive and more invasive but allows real-time-controlled observation with the option of tissue sampling and endoscopic treatment. DAE therapeutic options cover the whole range of widely used upper endoscopy and colonoscopy interventions.

**Double-balloon enteroscopy**
The DBE system (Fujinon Inc., Saitama, Japan) allows deep intubation of the small bowel by pleating the bowel onto a long, flexible enteroscope fitted with a specialized overtube. The enteroscope and the accompanying overtube have latex balloons at their distal end, which can be inflated and deflated with air from a pressure-controlled pump system. By alternating inflation and deflation of these two balloons, combined with instrument insertion and retraction, large portions of the small bowel can be pleated on the overtube using the so-called “push and pull” technique. Complete small-bowel visualization may generally be accomplished by a combined approach via the antegrade (oral) and retrograde (anal) route.

**Single-balloon enteroscopy**
The SBE system (Olympus Optical Co, Tokyo, Japan) uses only one latex-free balloon, which is attached to the distal end of the overtube. In contrast to the DBE device, there is no balloon attached at the enteroscope, and therefore a stable position of the device has to be maintained by a combination of endoscope tip angulation and suctioning into the small-bowel wall. The same “push and pull” technique as applied with the DBE system is used to pleat the small bowel onto the overtube, and to inspect on withdrawal.

**Spiral enteroscopy**
In spiral enteroscopy (Spirus Medical LLC, West Bridgewater, Massachusetts, USA), an enteroscope is passed through a disposable specialized overtube that has a spiral raised element at its distal end, which aids in the advancement of the enteroscope through the small bowel. The enteroscope can be locked in the overtube allowing the option of spiralling the overtube and enteroscope into the small bowel using clockwise rotation. Alternatively, the overtube can be unlocked, allowing the endoscope to be advanced into the small bowel through the overtube. Withdrawal is achieved by pulling the endoscope back to the 140-cm mark, and then gently rotating counterclockwise to draw back the scope.

**Balloon-guided enteroscopy**
The NaviAid AB device (SMART Medical Systems Ltd., Ra’anana, Israel) is an on-demand balloon catheter that is inserted through the 3.7-mm working channel of a standard colonoscope and enables it to advance deep into the small bowel in either an antegrade or retrograde approach. It consists of a balloon inflation/deflation system and a single-use latex-free balloon catheter, designed for anchoring in the small bowel. The balloon is inflated to anchor in the intestine and a repetitive push-pull technique is performed, with the endoscope sliding over the guiding catheter to the balloon inflated in the distal small bowel. The catheter may be removed to allow for therapeutic intervention while maintaining scope position. The balloon catheter can then be reinserted for further advancement.

**Intraoperative enteroscopy**
Intraoperative enteroscopy is an exploration of the small bowel with a flexible endoscope during a surgical procedure. The endoscope can be introduced either orally or via an enterotomy. The progression of the endoscope through the small intestine is facilitated by the manual external assistance of the surgeon.

**Recommendations and statements**
Evidence statements and recommendations are shown with a green background; main recommendations are in bold.
Obscure gastrointestinal bleeding

ESGE recommends small-bowel video capsule endoscopy as the first-line investigation in patients with obscure gastrointestinal bleeding (strong recommendation, moderate quality evidence).

Obscure gastrointestinal bleeding (OGIB) accounts for approximately 5% of all cases of gastrointestinal bleeding and is usually due to a lesion in the small bowel. There are few studies evaluating accuracy parameters (sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV], likelihood ratios) for small-bowel video capsule endoscopy (VCE) in occult and overt OGIB. However, the presently available evidence on the diagnostic usefulness of VCE is sufficient to support the use of VCE for OGIB [5, 6].

The accuracy parameters for VCE are uncertain because there is no standard comparative method; this in turn is related to the lack of a reliable criterion standard. In this context, the ideal criterion standard would be intraoperative enteroscopy, but the latter is associated with significant mortality and morbidity (5% and 17%, respectively) and it cannot be routinely recommended for diagnostic purposes in patients with OGIB [7]. For OGIB, there is only one trial that compares VCE and intraoperative enteroscopy and reports accuracy parameters (VCE sensitivity 95%, specificity 75%) [8]; there are a few studies comparing VCE with complete small-bowel exploration by device-assisted enteroscopy, and there is one trial that uses a combined criterion standard (including results of other procedures and/or outcomes during follow-up) [9–11]. For all these reasons, the diagnostic yield (i.e., the detection rate for what are thought to be clinically significant findings) is typically reported in small-bowel studies, as a proxy estimate of the diagnostic capability of VCE. There are limited data regarding differentiation of OGIB into occult vs. overt subtypes and thus the diagnostic yield for VCE in OGIB is generally reported as an overall value.

In a recently published updated meta-analysis [12], the reported pooled diagnostic yield for VCE was 61.7% (95%CI 47.3 – 76.1). Similarly, in a large systematic review, Liao et al. reported a “detection rate” for VCE in OGIB of 60.5% (95%CI 57.2 – 63.9) [13]. Earlier meta-analyses reported similar overall diagnostic yields for VCE in OGIB patients [14–16]. Several studies evaluating the diagnostic yields of the various methods for investigating the small bowel show that they are lower than that of VCE. Such studies are mostly retrospective and characterized by multiple bias. For this reason, we have based our assessment only on studies that directly compare VCE with other methods. Such comparisons are discussed in detail in the following paragraphs. Among the different methods considered, only device-assisted enteroscopy showed similar performances to that of VCE (see below); however, compared with VCE, device-assisted enteroscopy has a lower rate of complete examination of the small-bowel and is highly invasive. For these reasons it seems reasonable to recommend VCE as the first-line investigation in patients with OGIB (see Fig. 1).

A number of clinical factors have been reported to be associated with a higher diagnostic yield at VCE in patients with OGIB. Pennazio et al. [10] reported that the highest VCE yield was in patients with active bleeding (92.3%) or occult bleeding (44.2%), whereas patients with previous overt bleeding had the lowest yield (12.9%). A larger and more recent study confirmed that overt bleeding is the factor most strongly associated with a definitive diagnosis by VCE in OGIB [17]. Greater age, use of warfarin, and liver co-morbidity also seem to be related to a higher VCE yield [18, 19]. A multivariate analysis also showed that factors significantly associated with positive findings at VCE included a higher number of oesophagogastroduodenoscopies (OGDs) performed prior to VCE (odds ratio [OR] 1.17, 95%CI 1.00 – 1.37), increasing transfusion requirements (3–9 units, OR 1.70, 95%CI 1.08 – 2.66; and ≥ 10 units, OR 2.72, 95%CI 1.69 – 4.37), and connective tissue disease (OR 2.24, 95%CI 1.14 – 4.41) (all P < 0.045) [20].

In patients with OGIB, VCE showed an excellent safety profile: Liao et al. [13] reported a overall pooled retention rate of 1.4% (95%CI 1.2% – 1.6%) and a retention rate of 1.2% (95%CI 0.9% – 1.6%) in patients with OGIB. Thus routine small-bowel imaging

Guideline 355

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
or the use of the PillCam patency capsule (Covidien, Dublin, Ireland) is not essential prior to VCE in these patients.

In patients with overt obscure gastrointestinal bleeding ESGE recommends performing small-bowel capsule endoscopy as soon as possible after the bleeding episode, optimally within 14 days, in order to maximize the diagnostic yield (strong recommendation, moderate quality evidence).

Early performance of VCE appears to be an important factor, associated with significantly higher diagnostic yield compared with delayed VCE. There are no prospective studies addressing the relationship between timing of VCE and diagnostic yield. However, several retrospective studies, evaluating clinical outcome of patients with OGIB, have shown that earlier VCE contributes to higher diagnostic yield compared with delayed VCE. Two studies [10,18] addressing the higher yield of VCE with overt versus occult OGIB, also demonstrated that shorter intervals between the bleeding episode and performance of VCE increased the diagnostic yield, especially of clinically significant lesions. Katsinelos et al. [21] evaluated, whether timing of VCE, influences diagnostic yield. In their study, in patients with overt bleeding, the diagnostic yield was 14/16 (87.5%) in those who underwent VCE during the first 10 days following the bleeding episode, while it was only 1/9 (11.1%) for those who had VCE more than 10 days afterwards. Similar results were obtained by Bresci et al. [22] who demonstrated a positive yield of 92% when VCE was performed within 15 days after diagnosis of OGIB, compared with only 34% for VCE more than 15 days after diagnosis. This hypothesis has recently been confirmed in a group of 144 patients with overt OGIB, in whom early use of VCE within 3 days of hospital admission resulted in a significantly higher diagnostic yield [23]. In patients with occult OGIB it is often difficult to determine the actual length of the clinical history and there are no data that show a clear impact of timing of VCE on diagnostic yield.

ESGE recommends against push-enteroscopy as the first-line investigation in patients with obscure gastrointestinal bleeding, because of its lower diagnostic yield compared with small-bowel capsule endoscopy (strong recommendation, moderate quality evidence).

Because of capsule endoscopy’s excellent safety profile, patient tolerability, and potential for complete enteroscopy, ESGE recommends performance of small-bowel capsule endoscopy as the first-line examination, before consideration of device-assisted enteroscopy, when small-bowel evaluation is indicated for obscure gastrointestinal bleeding (strong recommendation, moderate quality evidence).

Compared with alternative modalities, VCE has been shown to be significantly superior to push-enteroscopy and both conventional and cross-sectional radiology, and to be as good as device-assisted enteroscopy in evaluating and finding the lesion(s) causing the bleeding. When VCE and push-enteroscopy were compared for the evaluation of OGIB, the diagnostic yield of VCE for “clinically significant findings” was 56% for VCE versus 26% for push-enteroscopy (incremental yield 30%, 95% CI 21%–38%, P<0.001) [14, 24]. However, the studies used to populate these meta-analyses have several limitations, such as the absence of a gold standard modality and subjective criteria for positive findings at VCE. There is only a single cross-over randomized controlled trial on this topic [25]. In that study, a definitive source of bleeding was identified in more patients in the VCE group than in the push-enteroscopy group (overall 50% vs. 24%; small-bowel-only 43% vs. 11%). Fewer lesions were missed by VCE than by push-enteroscopy. VCE missed no lesions in the small bowel, whereas all lesions missed lesions by push-enteroscopy were located in the small bowel. Patients who started with VCE were less likely to require the second investigation than were patients who initially underwent push-enteroscopy.

There has been no randomized controlled trial comparing the efficacy of VCE and double-balloon enteroscopy (DBE) in OGIB. However four meta-analyses comparing VCE and DBE have been published; comparison of the overall diagnostic yield between the two modalities gave the same result in all four meta-analyses [12,15,16,26]. In detail, when the diagnostic yield of VCE was compared with that of double-balloon enteroscopy in OGIB, the pooled diagnostic yield for VCE was 61.7% (95% CI 47.3–76.1) and for DBE it was 55.5% (95% CI 48.9–62.1) [12]. Compared with device-assisted enteroscopy, VCE has, however, a higher rate of complete enteroscopy and a lower rate of complications and it is less invasive. Although the clinical presentation may indicate the preferential endoscopic insertion route for device-assisted enteroscopy, VCE is also an effective tool for guiding the selection of the correct approach (oral vs. anal). The time point during transit of the capsule at which VCE identifies the lesion should guide the choice of the insertion route, even though different time thresholds have been proposed [27,28].

ESGE recommends performance of small-bowel capsule endoscopy as the first-line examination, before consideration of small-bowel radiographic studies or mesenteric angiography, when small-bowel evaluation is indicated for obscure gastrointestinal bleeding (strong recommendation, high quality evidence). Computed tomography enterography/enteroclysis may be a complementary examination to capsule endoscopy in selected patients (weak recommendation, low quality evidence).

VCE has been consistently demonstrated to be superior to small-bowel barium radiography in patients with OGIB. In what appears to be the only randomized controlled trial evaluating VCE versus small-bowel radiography in OGIB patients, the diagnostic yield was 30% with VCE versus 7% with dedicated small-bowel radiography (difference 23%; 95% CI 11%–36%) [29]. However, the primary study end point of further bleeding was not statistically different between groups, being 30% with VCE and 24% with radiography (difference 6%; 95% CI 0%–14%) [29]. Previously, Triester et al. [14] performed a meta-analysis comparing VCE versus small-bowel barium radiography (small-bowel follow-through [SBFT] or enteroclysis) and reported a diagnostic yield of “clinically significant findings” of 42% for VCE versus 6% for small-bowel barium radiography (incremental yield 36%, 95% CI 25%–48%; P<0.001). VCE is superior to mesenteric angiography/computed tomography (CT)-angiography in determining the cause of bleeding in patients with OGIB. In a randomized controlled trial comparing VCE versus angiography, Leung et al. [30] evaluated the diagnostic yield and long-term outcomes in 60 patients with overt OGIB.
The diagnostic yield for immediate VCE was significantly higher than for angiography, at 53.3% versus 20.0% (difference 33.3%, 95% CI 8.9%–52.8%). The cumulative risk of re-bleeding in the angiography and VCE group was 33.3% and 16.7%, respectively (P=0.10, log-rank test). There was no significant difference between the two groups in the long-term outcomes including further transfusion, hospitalization for re-bleeding, and mortality. Furthermore, Saperas et al. [31] reported on a prospective cohort study in which 28 consecutive patients admitted for OGB underwent both CT-angiography and standard enterographic angiography, followed by VCE. A source of bleeding was detected by VCE in a greater proportion of patients (diagnostic yield 72%, 95% CI 50.6–87.9%) than by CT-angiography (24%, 95% CI 9.4%–45.1%; P=0.005 vs. VCE), or by angiography (56%, 95% CI 34.9%–75.6%; P nonsignificant).

The diagnostic yields of VCE and CT-enterography/enteroclysis (CTE) may be dependent upon the underlying causes of OGB, thus CTE may be a complementary examination to VCE and could be helpful in determining the cause of OGB in selected patients. In a study by Agrawal et al. [32], 52 patients with OGB were prospectively enrolled to undergo CTE. CT-enterography was then performed in 25 patients in whom VCE had not identified a definitive source of bleeding. CTE did not identify the source of bleeding in any of the 11 patients with occult bleeding (0/11, diagnostic yield 0%) while the diagnostic yield was 50% (7/14) in patients with obscure overt bleeding (P<0.01), suggesting that when VCE is nondiagnostic, CTE may be useful for detecting a source of gastrointestinal bleeding in patients with overt, but not occult OGB. The superiority of VCE compared with CTE in OGB patients was also confirmed also in other studies with diagnostic yields of 57% and 63% for VCE and 30% and 21% for CTE [33, 34]. Conversely, Huprich et al. [35], prospectively comparing multiphasic CT-enterography and VCE in 58 OGB patients, reported that the sensitivity of CT-enterography was significantly greater than that of VCE (88% vs 38%, respectively; P=0.008), largely because CT-enterography found more small-bowel masses (100% vs. 33%, respectively; P=0.03). A few other small studies (prospective and retrospective case series) have failed to demonstrate any significant difference between VCE and CT-enteroscopy [36–38]. Finally, in a comparative study of 38 OGB patients, VCE was significantly superior to magnetic resonance enteroclysis for detecting abnormalities [39].

ESGE suggests that emergency small-bowel capsule endoscopy should be considered in patients with ongoing overt obscure gastrointestinal bleeding (weak recommendation, moderate quality evidence).

In such patients, ESGE suggests that device-assisted enteroscopy should also be considered as a possible first-line test, given that it allows diagnosis and treatment in the same procedure (weak recommendation, low quality evidence).

The prospect of utilizing VCE for severe ongoing overt OGB is appealing because of the relative safety, ease, and feasibility of the procedure in this setting. In addition, it has already been established, that early performance of VCE confers a superior diagnostic yield that translates to better patient management and out-
comes [10, 17, 18, 22, 26, 59]. Specifically with regard to urgent VCE, only two retrospective studies [60, 61] and one randomized controlled trial [30], involving fewer than 100 patients overall, have been reported so far. Based on limited data, emergency VCE, performed within 24–72 h from admission, during severe ongoing overt OGIB, appears to be an effective modality, with a diagnostic yield up to 70% and a significant impact on patient management.

Data are limited on the role of emergency device-assisted enteroscopy for the diagnosis and treatment of severe overt OGIB. In a small study of 10 patients with ongoing overt OGIB, emergency DBE was performed within 24 hours of clinical presentation and showed a diagnostic and therapeutic yield of 90% [56]. In a separate retrospective report of 120 patients with overt OGIB, urgent DBE was defined when the examination was done within 72 h after the last visible gastrointestinal bleeding; in this study the diagnostic yield in urgent DBE (70%, 52/74) was significantly higher than that in non-urgent DBE (30%, 14/46; P < 0.05) [62].

Notably, data from a small retrospective study showed that a combined approach, with emergency DBE guided in real time by VCE, is feasible in selected patients with acute overt OGIB [63]. Thus, in patients with ongoing overt OGIB, device-assisted enteroscopy should also be considered as first-line endoscopy, given the ability for diagnosis and treatment in the same procedure, and especially in centres where this modality is readily available and there is expertise in therapeutic enteroscopy. The optimal strategy for the evaluation of these patients remains undefined however, and this should be clarified with prospective studies.

Although several studies have reported a significant lesion detection rate for VCE in the stomach/duodenum or colon in OGIB patients, the limited available data suggest a low yield in those patients from systematic repeat oesophagogastroduodenoscopy (OGD) and/or ileocolonoscopy (i.e., second-look endoscopy) prior to VCE. Selby et al. reported on 92 patients with OGIB and showed that, at VCE, lesions were found as often in patients who had received only one preceding endoscopic evaluation as in those who had multiple endoscopic procedures [64]. Subsequently Gilbert et al., from this same author group, performed repeat endoscopies (OGD plus ileocolonoscopy) prior to VCE in 50 patients referred for the investigation of OGIB [65]. A probable cause of bleeding was found on repeat EGD in only 2/50 (4%) and repeat colonoscopy revealed no additional sources of bleeding. The authors concluded that the yield of repeat OGD and colonoscopy immediately prior to VCE is low when these procedures have previously been nondiagnostic. They also concluded that this approach was not cost-effective. Similarly, Vlachogiannakos et al. [66] in a retrospective analysis of 317 patients who underwent VCE for OGIB (after previous negative OGD and colonoscopy) reported that in 3.5% of cases, the source of bleeding was found in the stomach or the caecum. Routine repetition of conventional endoscopy before VCE was not a cost-effective approach.

To date, there are no time- or referral-based criteria for selecting patients in whom it may be worthwhile to perform second-look endoscopy before VCE. At the present time, the decision to perform second-look endoscopy before VCE in patients with OGIB or iron-deficiency anaemia (see below) should be taken only on a case-by-case basis.

ESGE recommends conservative management in those patients with obscure gastrointestinal bleeding (OGIB) and a negative small-bowel video capsule endoscopy (VCE) who do not have ongoing bleeding shown by overt bleeding or continued need for blood transfusions, since their prognosis is excellent and the risk of re-bleeding is low. ESGE recommends further investigation using repeat VCE, device-assisted enteroscopy, or computed tomography-enterography/enteroclysis for patients with OGIB and a negative VCE who have ongoing bleeding shown by overt bleeding or continued need for blood transfusions (strong recommendation, moderate quality evidence).

Up to one third of patients undergoing VCE for OGIB will have a negative VCE. Several studies have shown that in most patients with normal findings at VCE, re-bleeding rates and the need for transfusions are low. A total of 49 patients who underwent VCE for OGIB were followed up for a mean of 19 months; the overall long-term re-bleeding rate was 32.7%. The cumulative re-bleeding rate was significantly lower in patients with negative VCE (5.6%) than in patients with positive VCE (48.4%) [67]. In another study [68], 42 patients with OGIB were followed up for a mean of 17 months after VCE. The overall re-bleeding rate was 28%, and there was a statistically significant difference in re-bleeding rates between patients with positive findings (re-bleeding in 42%) and those with negative findings (re-bleeding in 11%); both in this last study and in another more recent report [69], anticoagulant use was associated with an increased risk of re-bleeding.

Although other studies on this topic have come to different conclusions [70] several reviews and consensus recommendations [71, 72] have concluded that patients with OGIB and normal findings at VCE should be managed conservatively without further investigation. Such conservative management may include a “wait and see” policy or iron supplementation or blood transfusions to restore haemoglobin levels.

Nevertheless, in cases of ongoing overt bleeding or continuing need for blood transfusions an alternative approach is warranted. In such patients, repeat VCE can yield a positive finding, and especially in patients with a drop in haemoglobin of at least 4 g/dL or in those with a change in clinical presentation from occult to overt bleeding [73]. Alternatively, device-assisted enteroscopy [74, 75] or CT-enterography/enteroclysis [32] can be performed after an initial negative VCE, and can yield a positive finding. At present there are no available data about the performance of CT-angiography in this setting. Similarly, there are no data about repeating upper and lower gastrointestinal endoscopy specifically in these patients although there is indirect evidence [65, 66] suggesting that these investigations can identify lesions previously overlooked. Randomized controlled trials comparing these modalities in the subgroup of patients with a nondiagnostic initial capsule study are still needed to clarify the most appropriate management.
In patients with positive findings at small-bowel capsule endoscopy, ESGE recommends device-assisted enteroscopy to confirm and possibly treat lesions identified by capsule endoscopy (strong recommendation, high quality evidence).

Teshima et al. [12] found that the pooled diagnostic yield of DBE performed after a previously positive VCE was 75.0% (95% CI 60.1%–90%); the odds ratio for the yield of DBE performed after a previously positive VCE, compared with that of DBE performed in all patients, was 1.79 (95% CI 1.09–2.96; P = 0.02). In that same study, a subgroup analysis revealed that the pooled diagnostic yield of DBE performed after a previously negative VCE was 27.5% (95% CI 16.7%–37.8%). In addition to its therapeutic possibilities, DBE has been reported to be helpful in clarifying the origin of bleeding when VCE shows only blood in the lumen or doubtful findings [76]. Although studies have assessed the diagnostic yield of VCE, push-enteroscopy, and device-assisted enteroscopy in OGIB, the precise significance of lesions identified and the impact on clinical outcome has not been consistently evaluated for those modalities. When we consider outcome in clinical practice, the emphasis should be on meaningful results. In the case of OGIB, a positive patient outcome should be either cessation of bleeding or resolution of anaemia. In addition, other important clinical outcomes for evaluation may include mortality and hemoglobin levels as well as the reduction in numbers of endoscopic procedures, hospitalizations, and blood transfusions. Several studies have demonstrated change in patient management and improved outcomes following VCE [10, 18, 19] and device-assisted enteroscopy [58, 77–81]. However, prospective comparative trials have not consistently confirmed these results [25, 29, 30].

Iron-deficiency anaemia

Iron-deficiency anaemia (IDA) occurs in 2%–5% of adult men and postmenopausal women in developed countries and is a common reason for referral to gastroenterologists [82]. According to the most recently published practice guidelines, upper and lower gastrointestinal endoscopies are inconclusive and small-bowel evaluation is indicated (strong recommendation, moderate quality evidence).

Iron-deficiency anaemia (IDA) occurs in 2% – 5% of adult men and postmenopausal women in developed countries and is a common reason for referral to gastroenterologists [82]. According to the most recently published practice guidelines, upper and lower gastrointestinal endoscopies are concurrent and the cornerstone of the investigation of IDA (particularly in postmenopausal women and all male patients). Bi-directional endoscopy identifies the cause of IDA in 70% – 80% of patients. When findings are negative, the small bowel is often targeted for further investigation [82]. Although there are no data comparing the effect of different selection criteria on the diagnostic performance of small-bowel video capsule endoscopy (VCE), the studies applying strict criteria tend to have a higher diagnostic yield [83 – 85]. Therefore, it is advisable that in patients with IDA referred for small-bowel evaluation, a complete work-up should be performed including: bi-directional endoscopy (with ileoscopy whenever possible); exclusion of coeliac disease (through serological and/or histopathological investigation); the taking of a complete past medical history (paying particular attention to medications and co-morbidities); gynaecological evaluation (for premenopausal women), and haematological evaluation.

In IDA patients, some authors have reported an increased incidence, higher than that reported in OGIB studies, of lesions detected by VCE that were within the reach of conventional endoscopy [86 – 89]; they also reported that after positive VCE, up to 30% of patients with lesions identified by VCE have been managed by repeating oesophagastroduodenoscopy or colonoscopy. Unfortunately, there is a lack of studies evaluating the cost-effectiveness of a systematic second-look endoscopy before small-bowel exploration in IDA patients. Therefore, at the present time, the decision to perform a second-look endoscopy before small-bowel exploration should be taken on a case-by-case basis. Recently published guidelines recommend an empirical trial of iron supplementation before referring patients for small-bowel evaluation [82]. Some initial data seem to support this policy, showing an increased diagnostic yield from VCE in patients in whom IDA persists or recurs after an empirical iron trial [90]. Nevertheless such a trial would lead to a diagnostic delay that might not be appropriate in some subgroups of patients (i.e. young patients or those with other associated gastrointestinal symptoms). Further large studies are needed to better clarify the diagnostic work-up to be performed before VCE in IDA patients. In patients with OGIB the role of the faecal occult blood test (FOBT) as a possible selection test has also been investigated. Unfortunately, studies are scarce and have yielded conflicting results [91, 92]. Further studies are needed and, at present, FOBT cannot be recommended as a screening tool to select patients for VCE.

In patients with positive findings at small-bowel capsule endoscopy, ESGE recommends device-assisted enteroscopy to confirm and possibly treat lesions identified by capsule endoscopy (strong recommendation, high quality evidence).
tients (half of the referrals for small-bowel exploration were for IDA), they reported that the yield of the diagnostic procedures was not significantly influenced by the nature of the OGB; therefore we can assume that VCE is superior to push-enteroscopy even when only IDA patients are concerned. Retrospective observational studies [97,99,103,104] reporting the diagnostic yield of push-enteroscopy in IDA, which is about 25%–35%, appear to support this hypothesis.

There are no head-to-head studies comparing device-assisted enteroscopy and VCE in IDA patients. Studies reporting the diagnostic yield of device-assisted enteroscopy, when used as a primary diagnostic tool in IDA, are scarce and include only a small number of patients [105]. Once again, looking at the diagnostic yield of device-assisted enteroscopy in OGB patients only (particularly those with obscure-occult bleeding), it appears to be comparable to that of VCE [12,15], especially when a complete enteroscopy is achieved [11]. Similar diagnostic yields might be reasonably expected in IDA patients, also.

In the setting of IDA there are two prospective studies comparing VCE and radiological examination head-to-head. Once again, this comparison is based on diagnostic yield rather than accuracy. VCE has been found to be significantly superior to small-bowel enteroclysis (diagnostic yield 56.9% vs. 11.8%, P < 0.001) [94] and to CT-enteroclysis (diagnostic yield: 77.8% vs. 22.2%, P < 0.01) [84]. The success of VCE over radiological techniques in IDA patients is mostly related to the nature of findings that, in 50%–60% of cases, are small flat vascular lesions [106]. There are no studies comparing magnetic resonance enterography/enteroclysis and VCE in IDA patients.

With regard to factors potentially associated with a positive diagnosis in IDA patients, a favourable association between increased VCE diagnostic yield and greater age and severity of anaemia has been found [83,95,96]; nevertheless, because of the incidence of important findings in young patients, age alone cannot be recommended as a reliable criterion for patient selection [96,107]. Potential positive associations between diagnostic yield of VCE and concomitant anti-coagulation therapy, as well as the presence of co-morbidities, have been suggested and need to be verified by further studies [83,95,96,108]. There are no data about factors affecting the diagnostic yield of device-assisted enteroscopy as the primary diagnostic tool in IDA patients.

At present, there are few studies evaluating the long-term outcome of IDA patients who undergo small-bowel evaluation. Furthermore, the existing studies are retrospective and heterogeneous in terms of patient characteristics, length of follow-up, modalities, and work-up done after the small-bowel examination. Two studies evaluating the impact of VCE in IDA patients [86,95], reported that overall VCE results led to changes in management, regardless of the result of VCE, in 44% and 60% of patients. This is more evident when the analysis is restricted to patients with positive VCE findings. Taking into account both specific therapeutic interventions and iron supplementation, change in management occurs in the large majority (up to 100%); however when specific interventions only are included (i.e., specific medical therapy, such as steroids, lanreotide, thalidomide, or gluten-free diet, or surgical/endoscopic therapy), changes in management are observed in 30%–50% of patients with positive VCE findings. Some studies [86,89,94] reported that the rate of resolution of anaemia at the end of follow-up is high (range 57%–86%), but yielded conflicting results when comparing patients with positive and negative VCE findings. While Apostolopoulos et al. [94] reported a significant difference in the rate of anaemia resolution between patients with positive and negative VCE findings (100% vs. 68%, P < 0.05), both Sheibani et al. [89] and Hollera et al. [86] did not find any difference between these two groups. There are no studies evaluating the clinical outcome of other diagnostic tools for small-bowel evaluation when used as the primary diagnostic method in IDA patients. Regarding safety in IDA patients, VCE has shown an excellent safety profile (similar to that observed in OGB; capsule retention range 0%–4% [84]), whereas there are no specific data about the safety of device-assisted enteroscopy in IDA patients. Nevertheless, a complication rate comparable to that observed in OGB patients can be expected for device-assisted enteroscopy. Regarding costs, there are no data on the cost-effectiveness of different diagnostic approaches for the evaluation of the small bowel in IDA patients. This is the main target for further studies, namely to take into account not only efficacy but also local costs and reimbursement policies, which differ widely among countries and health care systems.

**Crohn’s disease**

ESGE recommends ileocolonoscopy as the first endoscopic examination for investigating patients with suspected Crohn’s disease (strong recommendation, high quality evidence).

In patients with suspected Crohn’s disease and negative ileocolonoscopy findings, ESGE recommends small-bowel capsule endoscopy as the initial diagnostic modality for investigating the small bowel, in the absence of obstructive symptoms or known stenosis (strong recommendation, moderate quality evidence).

ESGE does not recommend routine small-bowel imaging or the use of the PillCam patency capsule prior to capsule endoscopy in these patients (strong recommendation, low quality evidence).

In the presence of obstructive symptoms or known stenosis, ESGE recommends that dedicated small-bowel cross-sectional imaging modalities such as magnetic resonance enterography/enteroclysis or computed tomography enterography/enteroscopy should be used first (strong recommendation, low quality evidence).

Up to 66% of patients with Crohn’s disease have small-bowel involvement at diagnosis [109] and in approximately 90% of patients with small-bowel Crohn’s disease, the disease involves the terminal ileum [110]. Thus, ileocolonoscopy is considered to be the first-line investigation for Crohn’s disease and is sufficient to establish the diagnosis in the vast majority of patients [109]. However, skip lesions of the terminal ileum may result in false-negative results at ileocolonoscopy [111] and small-bowel video capsule endoscopy (VCE) should therefore be considered when retrograde ileoscopy is not achieved or when lesions in the proximal small bowel must be excluded. VCE has been shown to have consistently high sensitivity and a high negative predictive value that ranges from 96% to 100% [112–116]. However, the lack of a gold standard for the diagnosis of Crohn’s disease hinders precise determination of VCE accuracy for this condition and “diagnostic yield” for findings consistent with Crohn’s disease has often been adopted as a surrogate in the appropriate clinical context. Furthermore, the mucosal inflammatory changes which are found in active small-bowel Crohn’s disease, are not specific to this dis-
ease and this has fuelled debate about where VCE should fit within the diagnostic algorithm for Crohn’s disease [117,118]. The high diagnostic yield of VCE compared with other imaging modalities might therefore not translate directly into a higher diagnostic accuracy since lesions detected by VCE might also be induced by other causes [119] such as nonsteroidal anti-inflammatory drugs (NSAIDs) in particular [120 – 124]. Moreover, VCE may detect minor mucosal breaks and erosions in up to one fifth of healthy individuals [113,125]. Nonetheless, VCE has been shown to compare favourably with small-bowel cross-sectional imaging for the detection of mucosal lesions consistent with Crohn’s disease [119,126].

In a meta-analysis conducted by Dionisio et al. [126] VCE was found to be superior to small-bowel follow-through (SBFT)/small-bowel enteroclysis and computed tomography enterography/enteroclysis (CTE), with significant weighted incremental yields in patients with suspected Crohn’s disease (VCE 52% vs. SBFT/small-bowel enteroclysis 16%, incremental yield 32%, \( P<0.0001, 95\%CI 16\% – 48\% ; VCE 68\% vs. CT-enterography 21\%, incremental yield 47\%, \( P<0.00001, 95\%CI 31\% – 63\% \)). A recent prospective study confirmed that VCE was better than SBFT and equivalent to ileocolonoscopy in detecting small-bowel inflammation in patients with suspected Crohn’s disease; this study also suggested that VCE can establish the diagnosis of Crohn’s disease in patients with proximal small-bowel inflammation, when ileocolonoscopy is negative [127]. Some recent studies have shown that VCE may be superior to magnetic resonance enterography/enteroclysis (MRE), particularly for the detection of early disease and proximal small-bowel lesions [128 – 130]. Although MRE and CTE have been shown to have a similar accuracy for the detection of inflammation in Crohn’s disease [131 – 135], MRE has the advantage of being free from ionizing radiation, a factor of increasing concern in the medical community [136] and increasing awareness amongst patients [137], but is limited by higher cost, longer examination time, and slightly inferior spatial resolution [131]. In a previous prospective, blinded randomized controlled trial by Solem et al. [138], which compared VCE, CTE, SBFT, and ileocolonoscopy in patients with known or suspected Crohn’s disease (using a consensus clinical diagnosis as the reference “gold standard”), the sensitivity of VCE and CTE was similar (83% for VCE, 67% for CTE and ileocolonoscopy, and 50% for SBFT) but the specificity of VCE was lower (53%) than that of all other tests (100%, \( P<0.05 \)). The results of this key study highlight the importance of interpreting VCE findings within an appropriate and well-defined clinical context.

The risk of capsule retention in patients with suspected Crohn’s disease but without obstructive symptoms or known stenosis and no history of small-bowel resection is low (~1.6%) and similar to that of patients who are being investigated for OGIB [13, 139 – 142]. In patients with suspected Crohn’s disease and a negative ileocolonoscopy, small-bowel stricturing disease is infrequent and in the absence of suspicious clinical symptoms, routine small-bowel imaging or use of the PillCam patency capsule prior to VCE is not essential. A careful clinical history may be the most useful way to determine the risk of capsule retention in this setting [140,143]. If patients with suspected Crohn’s disease present with obstructive symptoms or suspected/known stenosis, dedicated small-bowel cross-sectional imaging in the form of CTE or MRE (which may also provide additional evaluation of mural and extramural disease) should be the method of choice. VCE may still be used in this setting if functional pathology of the small-bowel is confirmed with the use of the PillCam patency capsule [144 – 146].

In the setting of suspected Crohn’s disease, ESGE recommends careful patient selection (using the clinical history and serological/faecal inflammatory markers) prior to small-bowel capsule endoscopy, in order to improve the diagnostic accuracy of capsule endoscopy for lesions consistent with active small-bowel Crohn’s disease (strong recommendation, low quality evidence). ESGE recommends discontinuation of nonsteroidal anti-inflammatory drugs (NSAIDs) for at least 1 month before capsule endoscopy since these drugs may induce small-bowel mucosal lesions indistinguishable from those caused by Crohn’s disease (strong recommendation, low quality evidence).

Careful patient selection remains crucial to increasing the specificity and positive predictive value (PPV) of VCE findings. At present, no specific index for the diagnosis of Crohn’s disease exists and although the presence of clinical symptoms remains an important trigger of the diagnostic process, abdominal pain or chronic diarrhoea alone rarely result in the detection of clinically significant small-bowel lesions at VCE [147,148]. Some more objective predictive clinical markers of small-bowel Crohn’s disease include the presence of weight loss [149], perianal disease [150], raised inflammatory markers [151 – 154], and faecal calprotectin levels [155 – 157]. The International Conference on Capsule Endoscopy (ICCE) [71] recommended that patients with suspected Crohn’s disease may be appropriate candidates for VCE only if they present with typical symptoms in addition to either extraintestinal manifestations of Crohn’s disease, raised serological/hematological inflammatory markers and/or iron deficiency, and/or abnormal small-bowel imaging findings (e.g. from SBFT and/or CTE/MRE).

Faecal calprotectin has recently been shown to be a sensitive marker of intestinal inflammation [158] and has potential as a cost-effective measure for selection of patients with suspected or known Crohn’s disease who are under consideration for VCE [155 – 157,159,160].

Use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be complicated by a drug-induced enteropathy with small-bowel mucosal erosion and ulceration which may lead to the formation of short, diaphragm-like strictures [161,162]. Several VCE studies have shown that use of NSAIDs (both nonselective and selective Cox-2 inhibitors) may be associated with a high incidence of small-bowel erosion and ulceration (of the order of 55% to 75%) [121 – 124,163 – 165]; chronic use of low dose aspirin has also been shown to be associated with the presence of similar small-bowel lesions [166,167]. Since the endoscopic appearances of small-bowel lesions induced by NSAIDs are endoscopically indistinguishable from lesions with other aetiologies such as Crohn’s disease, their presence may be confounding and potentially lead to misdiagnosis. In view of this, NSAIDs should be stopped before VCE, particularly if the patient is being investigated for the presence of active small-bowel Crohn’s disease. Although recommendations in the current literature are heterogeneous, arbitrarily stopping these agents for at least 1 month before VCE appears to be an acceptable prudent strategy [123].
In patients with established Crohn’s disease, based on ileocolonoscopy findings, ESGE recommends dedicated cross-sectional imaging for small-bowel evaluation since this has the potential to assess extent and location of any Crohn’s disease lesions, to identify strictures, and to assess for extraluminal disease (strong recommendation, low quality evidence). In patients with unremarkable or nondiagnostic findings from such cross-sectional imaging of the small bowel, ESGE recommends small-bowel capsule endoscopy as a subsequent investigation, if deemed to influence patient management (strong recommendation, low quality evidence).

When capsule endoscopy is indicated, ESGE recommends use of the PillCam patency capsule to confirm functional patency of the small bowel (strong recommendation, low quality evidence).

In patients with known Crohn’s disease, irrespective of the findings at ileocolonoscopy, further investigation is recommended to assess the extent and location of any Crohn’s disease lesions in the more proximal small bowel, since any positive findings may have prognostic and therapeutic implications [109]. Dedicated small-bowel cross-sectional imaging with CTE or MRE generally takes precedence over VCE for the evaluation of the small bowel in patients with established Crohn’s disease, since these modalities may also identify strictures and have the ability to assess the transmural and extraluminal nature of the disease and its anatomical distribution [117]. Dionisio et al. [126] showed in a meta-analysis that VCE was superior to SBFT/small-bowel enteroscopy and CTE in the evaluation of patients with known Crohn’s disease, with a significantly higher diagnostic yield (VCE 71% vs. SBFT/small-bowel enteroscopy 36%, incremental yield 38%, $P<0.00001$, 95%CI 22%–54%; VCE 71% vs. CTE 39%, incremental yield 32%, $P<0.0001$, 95%CI 16%–47% ). On the other hand, the diagnostic yield of VCE was found to be inferior to that of MRE, at 70% versus 79% (incremental yield –6%, $P=0.65$, 95%CI –30% to 19%). Nonetheless, VCE has been shown to improve the detection of lesions in the proximal small bowel when compared with both CTE and MRE [128,168] and may detect proximal small-bowel lesions in up to 50% of patients with previously diagnosed ileal Crohn’s disease [169]. Despite the suggestion from a recent study that CTE or MRE may be sufficient for the investigation of most patients with known small-bowel Crohn’s disease [170], VCE may still be of value if a Crohn’s disease flare-up is still suspected despite negative results from small-bowel cross-sectional imaging. In this context, VCE may be used as a further investigation if the presence of small-bowel mucosal lesions may influence patient management. Although prospective controlled trial data are lacking, a few retrospective studies have highlighted the potential impact of VCE on the management of patients with established Crohn’s disease [171–178].

The risk of capsule retention is increased and can be of the order of 13% in patients with known Crohn’s disease [13,140–142,179,180]. Although findings of small-bowel stenosis at CTE or MRE may preclude subsequent VCE in 27% to 40% of patients with known Crohn’s disease [131], not all strictures actually result in significant mechanical obstruction and the use of the PillCam patency capsule may help to identify patients who are at increased risk of capsule retention [144]. One retrospective study compared the performance of the patency capsule and radiological examinations in the detection of clinically significant small-bowel strictures [145]. In this study, the two methods were equivalent, suggesting that if cross-sectional imaging shows no stricture or the patency capsule is excreted intact, the patient will most probably pass the video capsule safely.

ESGE recommends initial conservative treatment in the case of capsule retention. ESGE recommends device-assisted enteroscopy if medical therapy has not led to promote spontaneous passage (strong recommendation, low quality evidence).

Cases of capsule retention can often be managed conservatively with anti-inflammatory agents and/or immunomodulators [181], resulting in spontaneous passage of the capsule [182]. If the capsule does not pass spontaneously after a trial of medical therapy, it may be retrieved by device-assisted enteroscopy [183,184]. If attempts at endoscopic capsule retrieval are unsuccessful and the patient is clinically well and without obstructive symptoms, an observant, conservative approach may be appropriate in this setting and only a minority of patients will need to undergo surgery to retrieve a retained capsule. In a large retrospective study of 2300 patients [185], including 301 with known Crohn’s disease of whom 196 (65.1%) had definite small-bowel involvement, capsule retention occurred in only 5 patients (1.6%). In 3 of these patients, the capsule passed spontaneously after a course of glucocorticoid therapy, while the other 2 patients required surgery for capsule retrieval.

ESGE suggests the use of activity scores (such as the Lewis score and the Capsule Endoscopy Crohn’s Disease Activity Index) to facilitate prospective small-bowel capsule endoscopy follow-up of patients for longitudinal assessment of the course of small-bowel Crohn’s disease and its response to medical therapy (using mucosal healing as an end point) (weak recommendation, low quality evidence).

The introduction of standardized quantitative scoring systems to describe the type, location, and severity of small-bowel lesions is being attempted [186]. The original threshold of ≥3 ulcers proposed by Mow et al. [114], although widely used, does not reflect the distribution or the severity of inflammatory activity, does not consider other inflammatory features such as oedema or stenosis, and has a modest positive predictive value of 50%–69% for the diagnosis of Crohn’s disease [113,171,187]. The Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI) score evaluates three parameters of small-bowel pathology in Crohn’s disease: inflammation, extent of disease, and presence of strictures, both for the proximal and distal segments of the small bowel, based on small-bowel transit time of the capsule. This score has been recently validated in a multicentre prospective study [188,189]. The Lewis score [190], which has also recently been validated [191], is a cumulative scoring system that is based on the presence and distribution of villous oedema, ulceration, and stenosis. It should be borne in mind that although these scoring systems can quantitatively describe the type, distribution, and severity of mucosal lesions, they cannot be used as a diagnostic tool per se [192]. In view of the nonspecific nature of small-bowel inflammatory lesions, the results of these scoring systems must be interpreted in the appropriate clinical context, in conjunction with other findings; it must be emphasised that a diagnosis of ac-
tive small-bowel Crohn's disease cannot be based upon the appearances seen only at VCE. Mucosal healing is increasingly recognised as an important end point for assessment of therapeutic efficacy in patients with inflammatory bowel disease (IBD). Recent clinical trials have begun to evaluate the potential role of VCE for assessment of mucosal healing in the small bowel [193–195], using quantitative scores such as the Lewis score [190] or CEDAI [189] for this purpose in research trials and clinical practice, analogously to the application to ileocolonoscopy of the Crohn's Disease Endoscopic Index of Severity (CDEIS) or the Simple Endoscopic Score (SES) for Crohn's disease [196].

The potential role of VCE in the assessment of patients with IBD unclassified (IBDU) has also been investigated. Although current data are scant, there is a suggestion that the findings at VCE may help to establish a definite diagnosis and small-bowel lesions compatible with Crohn's disease may be seen in up to 17%–70% of patients with this condition [171, 197–199]. However, it must be borne in mind that a negative VCE rules out only current disease activity and cannot definitely exclude a future diagnosis of Crohn's disease in these patients [200, 201].

In the natural course of Crohn's disease, intestinal resection is unavoidable in a significant proportion of patients. A majority of patients develop disease recurrence at or above the anastomosis and endoscopically detectable recurrence precedes the development of clinical symptoms. Although VCE has been shown to detect superficial proximal small-bowel lesions, undiagnosed by other modalities, in patients with Crohn's disease early after surgery, the clinical significance of these findings and how they may impact on patient management remains a matter of debate [202]. Therefore VCE should not at present replace ileocolonoscopy in the routine management of patients after surgery; it should be considered in the assessment of postoperative recurrence when ileocolonoscopy is unsuccessful or contraindicated [203–206].

**ESGE recommends device-assisted enteroscopy with small-bowel biopsy in patients with noncontributory ileocolonoscopy and with suspicion of Crohn's disease on small-bowel cross-sectional imaging modalities or small-bowel capsule endoscopy. Device-assisted enteroscopy with small-bowel biopsy is more likely to provide definitive evidence of Crohn's disease than cross-sectional imaging, although the latter offers a useful less invasive alternative that better defines transmural complication (strong recommendation, high quality evidence).**

Although there is no gold standard for the diagnosis of Crohn's disease and corroboration of clinical and investigative findings is required [109], the likelihood of its presence can be supported by the findings at ileocolonoscopy in the majority of patients with suspected Crohn's disease [119]. Dedicated small-bowel cross-sectional imaging (CTE or MRE) should be considered if symptoms raise suspicion for the presence of stricturing or perforating disease. These modalities are complementary to VCE which in turn is more sensitive in detecting mucosal inflammation [116, 126, 207]. Push-enteroscopy may provide direct endoscopic assessment and biopsies for histopathology especially in patients whose prior radiological or VCE findings suggest a lesion within the proximal small bowel [99, 208, 209]. Lesions that lie deeper in the small bowel, beyond the reach of ileocolonoscopy and push-enteroscopy, may be accessed by device-assisted enteroscopy which should be considered if histological assessment is needed to confirm a diagnosis of Crohn's disease or to exclude other conditions which mimic the appearance of Crohn's disease, such as infections or malignancy [210–215].

In the setting of suspected small-bowel Crohn's disease, the diagnostic yield of device-assisted enteroscopy ranges between 22% and 70% [210, 211, 216], being higher if the indication for device-assisted enteroscopy is based on previous small-bowel investigations (which may identify suspected lesions and guide the choice of insertion route) [211]. Two meta-analyses [15, 16] showed that VCE and double-balloon enteroscopy (DBE) have similar diagnostic yields. The authors concluded that in view of its noninvasive nature, VCE should be considered first. In the setting of patients with established Crohn's disease, the presence of small-bowel strictures may limit the safe use of VCE and as a result, device-assisted enteroscopy may be considered earlier in the evaluation of such patients [217]. Device-assisted enteroscopy may allow complete small-bowel examination and has a higher yield in patients where a high clinical index of suspicion for active Crohn's disease persists. In such a setting, compared with radiological modalities, device-assisted enteroscopy seems to be more accurate than small-bowel barium contrast studies [218] and MRE [219, 220]. As for other settings, positive findings at device-assisted enteroscopy were more likely if these investigations were guided by the findings of prior diagnostic imaging; this might also identify the optimal insertion route [28, 211, 221].

Device-assisted enteroscopy, however, is technically challenging, may require a bi-directional approach, deep sedation, or general anaesthesia and has a major complication rate of around 0.72% (which may be higher in patients with Crohn's disease) [222]. Therefore it should only be done if it might alter therapeutic strategy. In a small prospective trial, positive findings at device-assisted enteroscopy led to a step-up of medical therapy in 26 of 35 patients (74%), leading to clinical remission in 23 (88%) [217].

**ESGE recommends device-assisted enteroscopy if small-bowel endotherapy is indicated (including dilation of Crohn's disease small-bowel strictures, retrieval of foreign bodies, and treatment of small-bowel bleeding) (strong recommendation, low quality evidence).**

Reported indications for device-assisted enteroscopy in the setting of known or suspected Crohn's disease include diagnosis and therapeutic endoscopy in patients with bleeding [211, 218], balloon dilation of strictures in symptomatic patients, and retrieval of retained capsules [211, 223]. Technical success in dilating strictures that are accessible, less than 5 cm in length, and without severe inflammatory activity, is reported for between 60% and 80% of patients and repeat endoscopic balloon dilation may be undertaken [224–226], but long-term outcomes are less well known. Perforation rates following endoscopic balloon dilation of Crohn's disease-related strictures at device-assisted enteroscopy may be as high as 9% [224, 227–230].
ESGE recognises small-bowel capsule endoscopy/device-assisted enteroscopy and magnetic resonance or computed tomography enterography/enteroclysis as complementary strategies (weak recommendation, low quality evidence). Cost-effectiveness data regarding optimal investigation strategies for diagnosis of small-bowel Crohn’s disease are lacking.

Cost-effectiveness analyses are intended to support resource allocation decisions and are therefore dependent on local/regional socioeconomic perspectives [231]. Diagnostic techniques may affect patient outcomes indirectly by influencing subsequent management strategies, implying that benefits from a specific diagnostic test depend on performance characteristics (e.g. sensitivity and specificity) as well as other factors, such as prevalence of the disease and effectiveness of available treatments [232]. In Europe alone, Crohn’s disease directly results in a health care expenditure of between 4.6 to 5.6 billion euros per year. In addition to this, the indirect costs are estimated to be twice as high as the direct costs [233] and any delay in establishing the diagnosis may further increase this burden [234]. Therefore, mitigating this burden by cost-effective diagnostic and therapeutic strategies is paramount.

The use of high pre-test probability indicators in suspected small-bowel Crohn’s disease, for example application of the International Conference on Capsule Endoscopy (ICCE) criteria [71] with or without appropriate use of faecal inflammatory markers [155 – 157, 160, 235], may improve allocation of limited resources, and reduce the need for more invasive and expensive diagnostic investigations in patients with a low pre-test probability. In patients with strong suspicion of Crohn’s disease, ileocolonoscopy is the diagnostic method of choice for detecting colonic Crohn’s disease and/or disease activity in the terminal ileum. In order to establish disease extent at first presentation, further small-bowel imaging should be included in the diagnostic work-up; however the preferred, most cost-effective method for this remains unknown [236]. In about 10% of patients, Crohn’s disease only affects the small bowel proximal to the terminal ileum and disease activity in these patients may not be detected by ileocolonoscopy.

In patients with a negative ileocolonoscopy, the most cost-effective diagnostic algorithm with regard to small-bowel endoscopy versus dedicated cross-sectional imaging is still debated. Cost-effectiveness analysis of performing VCE immediately after ileocolonoscopy or only after dedicated small-bowel cross-sectional imaging in patients with suspected Crohn’s disease has produced conflicting results [237]. Although meta-analysis suggests a higher sensitivity and optimal negative predictive value for endoscopic methods compared with radiology, transmural and extramural lesions are only detected by dedicated small-bowel cross-sectional imaging [126] and the endoscopic and radiological technologies are therefore best considered to be complementary [238].

Cost-effectiveness comparisons of currently available small-bowel radiological investigations have also yielded conflicting results. Sensitivity analysis in one study suggested that in patients with a high prevalence of complications, MRE becomes as cost-effective as SBFT/small-bowel enteroclysis which although cheaper, is less accurate and may miss extramural disease while exposing patients to ionizing radiation [239]. A comparison of MRE and CTE showed that although MRE has the advantage of being radiation-free and allows dynamic evaluations of small-bowel peristalsis, it is a more expensive and longer examination with slightly inferior spatial resolution. In younger patients (≤50 years of age), MRE is likely to reach cost-effectiveness when compared with CTE; however low dose CTE may become an alternative cost-effective choice in the future [240].

Although cost-effectiveness comparisons of algorithms involving VCE and device-assisted enteroscopy in the setting of small-bowel bleeding have shown that capsule-directed device-assisted enteroscopy appears to be the most cost-effective strategy [241, 242], similar data for VCE versus device-assisted enteroscopy in the work-up of Crohn’s disease are lacking. Device-assisted enteroscopy also offers the potential for endotherapy (such as endoscopic balloon dilation of strictures) in patients with small-bowel Crohn’s disease, and this may considered as a beneficial and effective alternative to surgery in selected patients [224, 229]; however, cost-effectiveness or comparative studies of endoscopic versus surgical treatment of small-bowel strictures are not available.

Small-bowel tumours

ESGE recommends early use of small-bowel video capsule endoscopy in the search for a small-bowel tumour when obscure gastrointestinal bleeding and iron-deficiency anaemia are not explained otherwise (strong recommendation, moderate quality evidence).

Most small-bowel tumours are detected during work-up for obscure gastrointestinal bleeding (OGIB) or iron-deficiency anaemia (IDA), but are the cause in only about 3.5% – 5% of these patients [93], making these symptoms weak predictors. The clinical manifestations of small-bowel tumour, unfortunately, tend to be very nonspecific, and this can delay the diagnosis, especially in the early stages. Associated with a higher risk of small-bowel tumour are non-Hodgkin’s lymphomas as follicular lymphoma, haematologic metastasis of previously undiagnosed primary neuroendocrine tumor [243 – 245], and stage IV malignant melanoma, or stage III malignant melanoma with positive faecal occult blood test [246]. Coeliac disease that is complicated by anemia, that is refractory, or where there are persistent complaints despite a gluten-free diet, may be associated with T-cell lymphoma or adenocarcinoma [247,248] and might represent an indication for small-bowel capsule endoscopy (VCE).

Data on small-bowel endoscopy in small-bowel tumour are often retrieved as a small part from larger mixed series; the low percentage of small-bowel tumour findings compared with other findings in OGIB makes prospective trials almost impossible. A meta-analysis showed that VCE has a significantly higher diagnostic yield compared with push-enteroscopy in patients with OGIB [14]; however, regarding the small number of tumours included, VCE showed only a nonsignificant trend towards a higher diagnostic yield than push-enteroscopy. In a highly selected group of 30 patients, from 112 patients with small-bowel tumour detected by VCE, push-enteroscopy had a diagnostic yield of 70% [249]. Thus, push-enteroscopy could represent a reliable tool for further work-up of small-bowel tumour that is clearly localized to the proximal jejunum. In OGIB patients, the diagnostic yield of VCE is similar to that of double-balloon enteroscopy (DBE) [12, 15] and of intraoperative enteroscopy [8]. Translating these results also to the small subgroups of patients with small-bowel...
tumour included in these studies, VCE appears to be sufficiently accurate in detecting small-bowel tumours. Of note, concordance of findings between VCE and DBE was less good in patients with small-bowel tumour than in patients with inflammatory and vascular lesions [76]. Factors associated with diagnosis of small-bowel tumour by DBE were suspected tumour at radiological or VCE investigation, or evaluation or therapy of disease as lymphoma; but not associated were presence of stenotic symptoms, gender, or age. OGIB as the indication for investigation was significantly lower in patients with small-bowel tumour diagnosed at DBE [250]. Thus, DBE might be rather applied in a highly selected group, while VCE may serve as a selection tool for patients with small-bowel tumour in the large group with OGIB.

The risk of false-negative results in VCE should be always considered, being more frequent for small-bowel tumours and polyps in the duodenum and proximal jejunum, and for submucosal masses where a mucosal component is absent, such as neuroendocrine tumours or gastrointestinal stromal tumours (GISTs) [75, 244, 251 – 254].

VCE seems to be superior to small-bowel barium radiography [14, 249, 255]. Data concerning computed tomography-enterography/enteroclysis (CTE) and magnetic resonance-enterography/enteroclysis (MRE) are sparse and contradictory. MRE has been demonstrated to have high sensitivity (86%) and specificity (98%) for small-bowel tumours [256]. In a retrospective analysis of 77 patients, the specificity of MRE was higher than that of VCE (0.97 vs. 0.84, P = 0.047), whereas the sensitivity was similar (0.79 vs. 0.74, P = 0.591) [257]. A prospective blinded comparison in 58 patients with OGIB showed similar overall diagnostic yields for multiphase CTE at 28/58 (48%) and VCE at 25/58 (43%). However, CTE diagnosed 9/9 small-bowel tumours, while VCE found only 3 (33%) [35]. On the other hand, in patients with Lynch syndrome, VCE was superior to CTE in detecting small-bowel tumours, identifying one carcinoma and two adenomas, while CTE only raised suspicion of one carcinoma [258]. With specific reference to Lynch syndrome, it must be emphasized that although VCE has the potential to detect small-bowel neoplastic lesions, it may also miss these lesions [259]. Consequently, the role of VCE for surveillance of the small bowel in Lynch syndrome remains at present controversial.

Diagnosis of small-bowel tumours by VCE can be challenging. A retrospective analysis demonstrated that a proposed tumour score that took into account bleeding, mucosal disruption, an irregular surface, colour, and white villi was helpful in identifying small-bowel mass lesions [260]. A small prospective study applied a score for smooth protruding lesions, with the following criteria: ill-defined boundary with the surrounding mucosa, diameter larger than height, non-visible lumen in the frames in which the lesion appears, and an image lasting less than 10 minutes (Smooth, Protruding lesion Index on Capsule Endoscopy [SPICE] score). The score had a sensitivity of 83% and a specificity of 89%; however, 2 false-positive and 1 false-negative diagnoses of small-bowel tumour were still encountered [261]. Further larger prospective studies are needed to validate such scoring systems.

In the setting of suspicion of a small-bowel tumour, ESGE does not recommend specific investigations before small-bowel capsule endoscopy in patients without evidence for stenosis or previous small-bowel resection (strong recommendation, low quality evidence).

ESGE recommends consideration of device-assisted enteroscopy in preference to small-bowel capsule endoscopy if imaging tests have already shown suspicion of small-bowel tumour (strong recommendation, low quality evidence).

Most patients with small-bowel tumour detected at VCE had the indication of OGIB or IDA [262]. It can be borne in mind that: (a) only a minority of such patients have a neoplasm [249]; (b) the retention rate in small-bowel tumour is only slightly higher than in other bleeding disorders [142, 255]; (c) retention is in general asymptomatic [249]; and (d) most patients with small-bowel tumour will undergo surgical resection of the tumour (with the possibility of easy retrieval of a capsule). Therefore it does not seem justified to routinely perform tests to exclude stenosis before VCE in bleeding patients without clinical evidence for obstruction. Conversely, if there is already a suspicion of small-bowel tumour at imaging tests, device-assisted enteroscopy should be considered in preference to VCE, in order to avoid capsule retention and to obtain histological information.

ESGE recommends cross-sectional imaging to ascertain operability when there is a small-bowel capsule endoscopy finding of small-bowel tumour with a high diagnostic certainty. When there is uncertain diagnosis of small-bowel tumour at capsule endoscopy, biopsy sampling by device-assisted enteroscopy is required (strong recommendation, low quality evidence).

When a submucosal mass is detected by small-bowel capsule endoscopy, ESGE recommends confirmation of the diagnosis by device-assisted enteroscopy (strong recommendation, low quality evidence).

When capsule endoscopy shows high suspicion of submucosal mass and there is a negative but incomplete device-assisted enteroscopy, ESGE suggests cross-sectional imaging tests to confirm the diagnosis (weak recommendation, low quality evidence).

When there is a clear diagnosis of small-bowel tumour at VCE (ulcerated, bleeding mass lesion, stenosis) surgery without previous histological investigation seems justified. Cross-sectional imaging techniques should be requested to exclude inoperability. When protruding small-bowel lesions of uncertain nature are detected by VCE, device-assisted enteroscopy or imaging examinations are required, since innocent bulges may be confused with submucosal tumours (false-positive VCE findings). A tattoo placed during device-assisted enteroscopy may facilitate recognition of a small mass lesion at subsequent (laparoscopic) surgery [249].

Most studies on device-assisted enteroscopy and small-bowel tumours relate to DBE. Small series on single-balloon enteroscopy and spiral enteroscopy suggesting similar results need further confirmation. Device-assisted enteroscopy and VCE seem to have comparable sensitivity. A lower specificity of VCE seems to be related to the high rate of false-positive (mainly submucosal) masses. In a Chinese series, all 32 tumours detected by VCE and confirmed by DBE were further confirmed by surgery [28]; a further 6 submucosal tumours suspected at VCE were considered to...
be false-positive findings, as they were not confirmed by DBE. Two studies found that DBE was superior to computed tomography (CT) scan in the diagnosis of small-bowel tumours, including submucosal masses [263, 264]. In a series of 12 gastrointestinal stromal tumours (GISTs), the detection rates of DBE, VCE, and CT were 92%, 60%, and 67%, respectively. All cases, except for one incomplete study, were identified using DBE. One case was not diagnosed as a tumour because of the presence of extramural growth [254]. In a study of 159 patients with small-bowel tumours, VCE and DBE had significantly higher diagnostic yields than contrast-enhanced computed tomography (CECT), and DBE had significantly higher diagnostic yields than VCE, but a combination of CECT and VCE had a diagnostic yield similar to that of DBE [265].

In patients with treated follicular lymphoma, VCE was found to detect lesions at a similar rate to DBE; however, as identification of residual lymphoma required biopsy, the authors recommend DBE for follow-up [266]. Only one of 11 patients with a VCE diagnosis of malignant small-bowel tumour who underwent surgery had recurrent bleeding; in this patient it was caused by metastasis of gastric and papillary cancer in familial adenomatous polyposis (FAP) [267]. There are no studies to support regular follow-up of asymptomatic patients after resection of small-bowel tumour in the absence of inherited polyposis syndromes.

### Inherited polyposis syndromes

#### Familial adenomatous polyposis

**ESGE recommends against small-bowel capsule endoscopy in the follow-up of treated small-bowel tumours because of lack of data (strong recommendation, low quality evidence).**

In patients with treated follicular lymphoma, VCE was found to detect lesions at a similar rate to DBE; however, as identification of residual lymphoma required biopsy, the authors recommend DBE for follow-up [266]. Only one of 11 patients with a VCE diagnosis of malignant small-bowel tumour who underwent surgery had recurrent bleeding; in this patient it was caused by metastasis of gastric and papillary cancer in familial adenomatous polyposis (FAP) [267]. There are no studies to support regular follow-up of asymptomatic patients after resection of small-bowel tumour in the absence of inherited polyposis syndromes.

#### Peutz–Jeghers syndrome

**ESGE recommends small-bowel surveillance in patients with Peutz–Jeghers syndrome. Small-bowel capsule endoscopy and/or magnetic resonance enterography/enteroclysis appear adequate methods for this purpose, depending on local availability and expertise, or patient preference (strong recommendation, moderate quality evidence).**

The initial main purpose of small-bowel surveillance in Peutz–Jeghers syndrome (PJS) patients is to reduce the polyp burden and the likelihood of polyp-related complications, particularly intussusception. With advancing age, this focus may shift to the early detection of small-bowel cancer or precancerous lesions; however, the preventive effect of surveillance on development of such neoplasia remains to be proven [289, 290]. VCE has a greater sensitivity than small-bowel follow-through (SBFT) in detecting small-bowel polyps [291–293]. In comparison with MRE: VCE was superior at detecting small polyps; polyps > 1 cm were detected equally with both modalities, and location of polyps and determination of their exact sizes was more accurate with MRE [278, 279, 280]. MRE was also shown to be less prone to missing large polyps than VCE [294]. A small study reported a 93% concordance between MRE and enteroscopy (i.e. double-balloon enteroscopy (DBE), laparoscopic enteroscopy, or surgery) for larger (> 15 mm) and more risky polyps [296]. Compared with device-assisted enteroscopy, VCE has the advantage of allowing a more complete examination of the small bowel in...
Coeliac disease

Coeliac disease is a common autoimmune condition characterized by a heightened immunological response to ingested gluten, with prevalence rates in the United States and European populations estimated to range between 0.2% and 1% [310,311]. The current gold standard diagnostic test for coeliac disease is oesophagogastroduodenoscopy (OGD) with duodenal biopsies and small-bowel histology demonstrating the presence of villous atrophy (Marsh stage 3a to 3c) [312]. Corroborative evidence used to support the diagnosis of coeliac disease comes from positive serological tests (tissue transglutaminase [tTG] and endomysial antibodies [EMA]) and a clinical response to a gluten-free diet. Occasionally when diagnostic uncertainty exists, human leucocyte antigen (HLA) typing is undertaken which may help to exclude coeliac disease, given the high negative predictive value of this test.

OGD has several potential limitations as part of this diagnostic pathway. These include its invasive nature and the inability to evaluate small-bowel mucosa beyond the duodenum. Changes shown in coeliac disease are well-recognised to be patchy [313], and occasionally in some patients the small bowel distal to the reach of a standard gastroscope may be more affected than the proximal bowel where biopsies are taken [314–316]. There has been increasing interest in the role small-bowel video capsule endoscopy (VCE) may have in coeliac disease. With 8-fold magnification power comparable to that of a dissecting microscope, VCE has the potential to detect villous atrophy and other small-bowel complications seen in coeliac disease.

Studies assessing the utility of VCE in diagnosing coeliac disease have reported the following diagnostic values for VCE: sensitivity 70%–100%; specificity 64%–100%; positive predictive value (PPV) 96%–100%; and negative predictive value (NPV) 71%–93% [314,317–320]. A consistent finding in all of these studies is that, in the presence of EMA or significantly elevated tTG, the PPV and specificity for the recognition of endoscopic markers of coeliac disease are 100%. However, the high pre-test probability of coeliac disease in all of these studies may again be a potential limitation leading to an overestimation of VCE performance. Nevertheless, they accurately reflect real-life clinical practice where patients are likely to be selected for VCE on the basis of positive serological results, and suggest that VCE may be an appropriate tool for patients who are unable to undergo OGD.

ESGE recommends device-assisted enteroscopy with timely polypectomy when large polyps (>10 – 15 mm) are discovered by radiological examination or small-bowel capsule endoscopy in patients with Peutz–Jeghers syndrome (strong recommendation, moderate quality evidence).

It is now well acknowledged that polyp size is the most important risk factor for small-bowel intussusception with intestinal obstruction, and that intussusception is generally due to polyps ≥15mm in diameter [301–303]. Consequently, large polyps (10–15 mm) or symptomatic or rapidly growing polyps should be removed. Device-assisted enteroscopy is clinically useful for diagnosis and relatively safe for therapy of small-bowel polyps in PJS patients, both in adults and in children [286,301,304–308].

A study described 29 diagnostic and therapeutic DBE procedures in 13 patients with PJS, with removal of multiple polyps >1 cm [304] without complications. However, two other studies, report a complication rate of up to 6.8%, including acute pancreatitis (2.7%) [306] and post-polypectomy syndrome (5%) [305].

In PJS, completeness of small-bowel investigation by device-assisted enteroscopy may be jeopardized by previous laparotomies [303]. If there is no information on polyp burden, from the age of 8 – 10 years [289,290,302,309], an initial VCE/MRE may be preferred to select for device-assisted enteroscopy only those patients with a need for therapy. When there is a high polyp burden, and incomplete polypectomy during a device-assisted enteroscopy, the next surveillance might preferably also be done by device-assisted enteroscopy, as this is more cost-effective in a setting where a high proportion of procedures are therapeutic. Indeed, repeated DBE examinations have been reported to reduce small-bowel polyp burden and to prevent polyp-related complications such as intussusception [304–306]. When a polyp is too large for safe removal with device-assisted enteroscopy or cannot be reached using this modality, intraoperative enteroscopy could be considered for polypectomy or enterotomy.

ESGE recommends that there is no role for small-bowel capsule endoscopy in assessing the extent of disease or response to a gluten-free diet (strong recommendation, low quality evidence).

One area where VCE may confer an advantage over standard endoscopy is that VCE has the potential to image the entire small bowel. Intuitively it would seem that the more of the bowel that is affected, the more severe the symptoms and the higher the chance of potential complications. However this has not been proven, mainly because it is difficult to assess the extent of disease. VCE may provide a way of doing this. In a study of 38 patients with untreated coeliac disease and 38 controls [314], the authors were unable to show a relationship between either qualitative or quantitative assessments of extent of disease and severity of clinical presentation; however a positive EMA result was associated with more extensive disease. In the 30 coeliac disease patients who agreed to repeat VCE after adopting a gluten-free diet, the mean time in which abnormality was observed reduced from 60 minutes to 12 minutes. A second more recent study of 12 patients with coeliac disease who had repeat VCE after 12 months on a gluten-free diet has also demonstrated such an improvement [319]. Although there was no initial corre-
lation between extent of disease and clinical severity, they did demonstrate a significant reduction in the mean time in which villous atrophy was observed. On the evidence of these two studies, so far no relationship between extent of small-bowel involvement and clinical severity of disease has been demonstrated. As experience with VCE in coeliac disease increases, however, such a demonstration may become possible.

ESGE suggests the use of small-bowel capsule endoscopy in cases of equivocal diagnosis of coeliac disease (weak recommendation, low quality evidence).

Another area where VCE may play a role is in the investigation of cases with equivocal diagnosis of coeliac disease. The changes of coeliac disease can be patchy and a duodenal biopsy in patients with positive serological findings might not demonstrate villous atrophy. Lesser degrees of histological abnormality that can be associated with coeliac disease are nonspecific and are seen in a variety of other conditions. This can leave some patients without a definitive diagnosis. In a study of 8 patients with positive serological results (EMA or TTG) and normal findings from duodenal biopsy, VCE did not reveal any endoscopic features of coeliac disease [319]. Thus the investigators concluded that there was no benefit in performing VCE for this subgroup of patients; another similar study came to the same conclusions [321]. There is however conflicting evidence. In a further study of 30 patients by Kurien et al. with Marsh stage 1 or 2 changes, only 6 of whom had positive EMA or tTG results, one patient was diagnosed with coeliac disease and another with small-bowel Crohn’s disease on the basis of VCE appearances [322]. It is clear that further work is required to assess the cost-effectiveness of the use of VCE in these equivocal cases if the yield is as low as in the study by Kurien et al. VCE use may be justified however, in patients who are positive for EMA or tTG positive patients who have Marsh stage 1 or 2 changes or gastrointestinal symptoms, particularly if they are unwilling to undergo further OGD and repeat biopsies. Patients with antibody-negative villous atrophy represent another diagnostic challenge since there is a wide range of differential diagnoses for villous atrophy. In the study of equivocal cases by Kurien et al. [322] they also included a group of patients with antibody-negative villous atrophy to see whether this increased the diagnostic yield. Patients were extensively investigated for coeliac disease including human leukocyte antigen (HLA) pheno-typing, by monitoring their response to a gluten-free diet and, in some cases, repeat duodenal biopsies. On the basis of VCE appearances and other ancillary tests, 7 patients could be diagnosed with coeliac disease and 2 further patients were diagnosed with small-bowel Crohn’s disease as a cause for villous atrophy. Again this is a single small study and further work needs to be done to clarify the role of VCE in antibody-negative villous atrophy cases. This is particularly important as VCE alone is probably insufficient to confirm a diagnosis of coeliac disease, given that endoscopic markers are not specific to coeliac disease and are, rather, predictors of mucosal disease [323].

ESGE recommends initial assessment by small-bowel capsule endoscopy followed by device-assisted enteroscopy in nonresponsive or refractory coeliac disease (strong recommendation, low quality evidence).

The distribution of serious complications of coeliac disease such as refractory coeliac disease and enteropathy-associated T-cell lymphomas (EATLs) is particularly important as these appear to be more commonly seen in the distal small bowel [324–328]. Ulcerative jejunitis is usually associated with refractory coeliac disease type II and with a high risk of developing EATL. Early identification of refractory coeliac disease type II may allow effective treatment with immunosuppression and prevent progression to EATL. VCE could therefore play a role in the investigation of these patients. In two studies of patients with coeliac disease and persisting symptoms, a few serious complications were identified by VCE including cases of EATL, ulcerative jejunitis, and refractory coeliac disease types I and II, some of which were confirmed by double-balloon enteroscopy (DBE) and biopsy [322, 325]. The use of VCE to assess the extent and severity of disease in patients with known refractory coeliac disease may also be helpful, as shown in a recent study of 29 patients with refractory coeliac disease and 9 patients with symptomatic coeliac disease [248]. In the refractory coeliac disease cohort, 3 cases of EATL were identified and 5 cases of ulcerative jejunitis requiring specific treatment. The majority of the refractory coeliac disease patients also underwent device-assisted enteroscopy and the authors concluded that, on the basis of VCE findings, 17 patients could have avoided this invasive investigation. Apart from the latter study [248], where there was an unusually high proportion of patients with refractory coeliac disease, the apparent diagnostic yield for complications such as EATL and ulcerative jejunitis appears low. However these diagnoses carry significant rates of morbidity and mortality which may be reduced by prompt diagnosis. The use of capsule endoscopy followed by device-assisted enteroscopy [329,330] in patients with nonresponsive disease may therefore be justified.

Patients with ulcerative jejunitis and EATL can have a significant risk of small-bowel stricturing. VCE should be used with caution therefore and a patency capsule should always be employed to reduce the incidence of capsule retention. Magnetic resonance enteroscopy has also been suggested for the detection of malignancies related to coeliac disease [331].

ESGE guidelines represent a consensus of best practice based on the available evidence at the time of preparation. They may not apply in all situations and should be interpreted in the light of specific clinical situations and resource availability. Further controlled clinical studies may be needed to clarify aspects of these statements, and revision may be necessary as new data appear. Clinical consideration may justify a course of action at variance to these recommendations. ESGE guidelines are intended to be an educational device to provide information that may assist endoscopists in providing care to patients. They are not rules and should not be construed as establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any particular treatment.
Competing interests: J. Albert, research funding from Coviden (formerly Given Imaging); J. P. Charton, speaker for Coviden; R. Eliakim, paid consultant for Coviden; I. Grainik, paid consultant for and research funding from Coviden; M. McAlindon, co-director of CapsuleReader Ltd; M. Pennazio, speaker for Coviden.

Institutions
1 Division of Gastroenterology, San Giovanni Battista University Teaching Hospital, Turin, Italy
2 Digestive Endoscopy Unit, Catholic University, Rome, Italy
3 Department of Gastroenterology, Chaim Sheba Medical Center, Sacker School of Medicine, Tel-Aviv University Tel-Hashomer, Israel
4 Klinik für Innere Medizin, Bethesda Krankenhaus Bergedorf, Hamburg, Germany
5 Department of Medicine II, Sana Klinikum, Offenbach, Germany
6 Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands
7 Gastroenterology Unit, Ospedale Valduce, Como, Italy
8 Division of Gastroenterology, Sharee Zedek Medical Center, Jerusalem, Israel
9 Department of Medicine I, Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany
10 Assistance Publique-Hôpitaux de Paris, Hôpital Édenvalence Georges-Pompidou, Service d’Hépato-gastro-entérologie, Paris, France
11 Medizinische Klinik, Evangelisches Krankenhaus, Düsseldorf, Germany
12 Department of Hepato-Gastroenterology, Nouvel Hôpital Civil, University Hospital of Strasbourg, Strasbourg, France
13 Royal Free Unit for Endoscopy and Centre for Gastroenterology, The Royal Free Hospital and University College London, London, UK
14 Department of Medicine B, University of Münster, Münster, Germany
15 Institute of Gastroenterology and Liver Diseases, Ha’mek Medical Center Afúla, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology Haifa, Israel
16 Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
17 Gastroenterology Department, Centro Hospitalar do Alto Ave, Guimarães, Portugal.
18 Clinical Psychology Unit, Department of Psychology, University of Sheffield.
19 Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France
20 Gdyet Endoscopy Center, Buenos Aires, Argentina
21 Department of Gastroenterology, Nuovo Regina Margherita Hospital, Rome, Italy

References
10 Pennazio M, Santucci R, Rondonotti E et al. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: report of 100 consecutive cases. Gastroenterology 2004; 126: 643–653
11 Shishido T, Oka S, Tanaka S et al. Diagnostic yield of capsule endoscopy vs. double-balloon endoscopy for patients who have undergone total-# enteroscopy with obscure gastrointestinal bleeding. Hepatogastroenterology 2012; 59: 955–959


Tee HP, Raffles AJ. Non-small-bowel lesions encountered during double-balloon enteroscopy performed for obscure gastrointestinal bleeding. World J Gastroenterol 2010; 16: 1895–1898


Chen LH, Cao HJ, Zhang H et al. [Diagnostic values of double-balloon enteroscopy and abdominal computed tomography in small bowel disease]. Zhonghua Yi Xue Za Zhi 2008; 88: 3305–3308


Aniwam S, Viriyavuthakul V, Kerkmimrit R et al. Urgent double balloon endoscopy provides higher yields than non-urgent double balloon endoscopy in overt obscure gastrointestinal bleeding. Endoscopy International Open 2014; 02: E90–E95


Selby W. Can clinical features predict the likelihood of finding abnormalities when using capsule endoscopy in patients with GI bleeding of obscure origin? Gastrointest Endosc 2004; 59: 782–787


Chung AK, Chin BW, Meredith CG. Clinically significant small-bowel pathology identified by double-balloon enteroscopy but missed by capsule endoscopy. Gastrointest Endosc 2006; 64: 445–449


Williamson JB, Judith JR, Caidos JK et al. Prospective evaluation of the long-term outcomes after deep small-bowel spiral enteroscopy in pa...
patients with obscure GI bleeding. Gastrointest Endosc 2012; 76: 771–778


Bain GH, Ritchie VP, Salunche SS et al. The use of small bowel capsule endoscopy in the investigation of iron deficiency anaemia. Adherence to BSG guidelines and impact on diagnostic yield. United European Gastroenterol J 2014; 02: A217


Apostolopoulos P, Liu HZ, Croll E et al. The role of wireless capsule endoscopy in investigating unexplained iron deficiency anaemia after negative endoscopic evaluation of the upper and lower gastrointestinal tract. Endoscopy 2006; 38: 1127–1132

Sidhu PS, McAlindon M, Drew K et al. Diagnostic yield of small-bowel capsule endoscopy in patients with iron deficiency anaemia: does it affect management? Gastrointest Endosc 2013; 78: 800–801


Zuckerman GR, Prakash C, Aksin MP et al. AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000; 118: 201–221


Sidhu PS, McAlindon M, Drew K et al. The utility of capsule endoscopy in patients with iron deficiency anaemia under 50 years – is the juice worth the squeeze? Gut 2013; 62 Suppl 1: A287


Leighton JA. The role of endoscopic imaging of the small bowel in clinical practice. Am J Gastroenterol 2011; 106: 27–36

Lewis BS, Eisen GM, Friedman S. A pooled analysis to evaluate results of capsule endoscopy trials. Endoscopy 2005; 37: 960–965


Toth E, Németh A, Nielsen J et al. Capsule endoscopy is superior to magnetic resonance enterography for detection of Crohn’s lesions in the small bowel. Gut 2011; 60: A404


Adler SN, Youn M, Einton S et al. Does capsule endoscopy have an added value in patients with perianal disease and a negative work up for Crohn’s disease? World J Gastrointest Endosc 2012; 4: 185–188


Simpponen T, Haapamaki J, Savilahti E et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn’s disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012; 47: 778–784


van Rhenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369


Pennazio M. Capsule endoscopy: where are we after 6 years of clinical use? Dig Liver Dis 2006; 38: 867 – 878


Mann NK, Lo SK. Wireless capsule endoscopy improves outcomes in nonstricturing Crohn’s disease: an evaluation of pre- and post-treatment capsule endoscopy (CE). Gastrointest Endosc 2013; 77: A8275


Henriksen M, Johnsen J, Lygren I et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol 2006; 41: 1037 – 1043


Darbari A, Kalloo AN, Cuffari C. Diagnostic yield, safety, and efficacy of push enteroscopy in pediatrics. Gastrointest Endosc 2006; 64: 224 – 228


Guideline
Gastrointest Endosc 2012; 74: 563 – 570


Appendices e1, e2 and e3

online content viewable at: www.thieme-connect.de